Literature DB >> 27444219

CHA2 DS2 -VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm.

Siqin Ye1, Min Qian2, Bo Zhao2, Richard Buchsbaum2, Ralph L Sacco3, Bruce Levin2, Marco R Di Tullio4, Douglas L Mann5, Patrick M Pullicino6, Ronald S Freudenberger7, John R Teerlink8, J P Mohr9, Susan Graham10, Arthur J Labovitz11, Conrado J Estol12, Dirk J Lok13, Piotr Ponikowski14, Stefan D Anker15, Gregory Y H Lip16, John L P Thompson2, Shunichi Homma4.   

Abstract

AIMS: The aim of this study was to determine whether the CHA2 DS2 -VASc score can predict adverse outcomes such as death, ischaemic stroke, and major haemorrhage, in patients with systolic heart failure in sinus rhythm. METHODS AND
RESULTS: CHA2 DS2 -VASc scores were calculated for 1101 patients randomized to warfarin and 1123 patients randomized to aspirin. Adverse outcomes were defined as death or ischaemic stroke, death alone, ischaemic stroke alone, and major haemorrhage. Using proportional hazards models, we found that each 1-point increase in the CHA2 DS2 -VASc score was associated with increased hazard of death or ischaemic stroke events [hazard ratio (HR) for the warfarin arm = 1.21, 95% confidence interval (CI) 1.13-1.30, P < 0.001; for aspirin, HR = 1.20, 95% CI 1.11-1.29, P < 0.001]. Similar increased hazards for higher CHA2 DS2 -VASc scores were observed for death alone, ischaemic stroke alone, and major haemorrhage. Overall performance of the CHA2 DS2 -VASc score was assessed using c-statistics for full models containing the risk score, treatment assignment, and score-treatment interaction, with the c-statistics for the full models ranging from 0.57 for death to 0.68 for major haemorrhage.
CONCLUSIONS: The CHA2 DS2 -VASc score predicted adverse outcomes in patients with systolic heart failure in sinus rhythm, with modest prediction accuracy.
© 2016 The Authors. European Journal of Heart Failure © 2016 European Society of Cardiology.

Entities:  

Keywords:  Bleeding; Heart failure; Sinus rhythm; Stroke; Warfarin

Mesh:

Substances:

Year:  2016        PMID: 27444219      PMCID: PMC5053869          DOI: 10.1002/ejhf.613

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  18 in total

1.  Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.

Authors:  Line Melgaard; Anders Gorst-Rasmussen; Deidre A Lane; Lars Hvilsted Rasmussen; Torben Bjerregaard Larsen; Gregory Y H Lip
Journal:  JAMA       Date:  2015-09-08       Impact factor: 56.272

2.  Warfarin in heart failure.

Authors:  John W Eikelboom; Stuart J Connolly
Journal:  N Engl J Med       Date:  2012-05-02       Impact factor: 91.245

3.  A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model.

Authors:  S May; D W Hosmer
Journal:  Lifetime Data Anal       Date:  1998       Impact factor: 1.588

4.  Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.

Authors:  Azmil H Abdul-Rahim; Ana-Cristina Perez; Rachael L Fulton; Pardeep S Jhund; Roberto Latini; Gianni Tognoni; John Wikstrand; John Kjekshus; Gregory Y H Lip; Aldo P Maggioni; Luigi Tavazzi; Kennedy R Lees; John J V McMurray
Journal:  Circulation       Date:  2015-03-25       Impact factor: 29.690

5.  Stroke and anticoagulation in heart failure without atrial fibrillation: from risk to opportunity.

Authors:  Shunichi Homma; Siqin Ye
Journal:  Circulation       Date:  2015-03-25       Impact factor: 29.690

6.  Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation.

Authors:  Mark H Eckman; Daniel E Singer; Jonathan Rosand; Steven M Greenberg
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-12-07

7.  Warfarin and aspirin in patients with heart failure and sinus rhythm.

Authors:  Shunichi Homma; John L P Thompson; Patrick M Pullicino; Bruce Levin; Ronald S Freudenberger; John R Teerlink; Susan E Ammon; Susan Graham; Ralph L Sacco; Douglas L Mann; J P Mohr; Barry M Massie; Arthur J Labovitz; Stefan D Anker; Dirk J Lok; Piotr Ponikowski; Conrado J Estol; Gregory Y H Lip; Marco R Di Tullio; Alexandra R Sanford; Vilma Mejia; Andre P Gabriel; Mirna L del Valle; Richard Buchsbaum
Journal:  N Engl J Med       Date:  2012-05-02       Impact factor: 91.245

Review 8.  Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials.

Authors:  Qinmei Xiong; Yee Cheng Lau; Keitaro Senoo; Deirdre A Lane; Kui Hong; Gregory Y H Lip
Journal:  Eur J Heart Fail       Date:  2015-09-03       Impact factor: 15.534

9.  Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure - Subanalysis of the WARCEF Trial.

Authors:  Tomoko S Kato; Marco R Di Tullio; Min Qian; Mengfei Wu; John L P Thompson; Douglas L Mann; Ralph L Sacco; Patrick M Pullicino; Ronald S Freudenberger; John R Teerlink; Susan Graham; Gregory Y H Lip; Bruce Levin; Jay P Mohr; Arthur J Labovitz; Conrado J Estol; Dirk J Lok; Piotr Ponikowski; Stefan D Anker; Shunichi Homma
Journal:  Circ J       Date:  2016-01-22       Impact factor: 2.993

10.  Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial.

Authors:  Faiez Zannad; Barry Greenberg; John G F Cleland; Mihai Gheorghiade; Dirk J van Veldhuisen; Mandeep R Mehra; Stefan D Anker; William M Byra; Min Fu; Roger M Mills
Journal:  Eur J Heart Fail       Date:  2015-04-27       Impact factor: 15.534

View more
  9 in total

1.  Prediction of acute coronary syndrome, ischemic stroke, and mortality in patients with heart failure: a comparison of CHA2DS2-VASc and AHEAD scores.

Authors:  Wei-Syun Hu; Cheng-Li Lin
Journal:  J Interv Card Electrophysiol       Date:  2019-06-14       Impact factor: 1.900

2.  Comparison of CHA2DS2-VASc and AHEAD scores for the prediction of incident dementia in patients hospitalized for heart failure: a nationwide cohort study.

Authors:  Wei-Syun Hu; Cheng-Li Lin
Journal:  Intern Emerg Med       Date:  2018-10-10       Impact factor: 3.397

3.  Response by Di Tullio et al to Letter Regarding Article, "Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial".

Authors:  Marco R Di Tullio; John L P Thompson; Shunichi Homma
Journal:  Stroke       Date:  2016-11-01       Impact factor: 7.914

Review 4.  Heart Failure and Stroke.

Authors:  Katja Schumacher; Jelena Kornej; Eduard Shantsila; Gregory Y H Lip
Journal:  Curr Heart Fail Rep       Date:  2018-10

5.  Value of the CHA2DS2-VASc score and Fabry-specific score for predicting new-onset or recurrent stroke/TIA in Fabry disease patients without atrial fibrillation.

Authors:  Dan Liu; Kai Hu; Marie Schmidt; Jonas Müntze; Octavian Maniuc; Daniel Gensler; Daniel Oder; Tim Salinger; Frank Weidemann; Georg Ertl; Stefan Frantz; Christoph Wanner; Peter Nordbeck
Journal:  Clin Res Cardiol       Date:  2018-05-24       Impact factor: 5.460

6.  Predicting stroke and death in patients with heart failure using CHA2DS2-VASc score in Asia.

Authors:  Mi Kyoung Son; Nam-Kyoo Lim; Hyun-Young Park
Journal:  BMC Cardiovasc Disord       Date:  2019-08-08       Impact factor: 2.298

7.  Modified CHA2DS2-VASc score predicts in-hospital mortality and procedural complications in acute coronary syndrome treated with percutaneous coronary intervention.

Authors:  Ashraf Abugroun; Abdalla Hassan; Safwan Gaznabi; Hakeem Ayinde; Ahmed Subahi; Mohammed Samee; Adhir Shroff; Lloyd W Klein
Journal:  Int J Cardiol Heart Vasc       Date:  2020-05-17

8.  A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.

Authors:  Mandeep R Mehra; Muthiah Vaduganathan; Min Fu; João Pedro Ferreira; Stefan D Anker; John G F Cleland; Carolyn S P Lam; Dirk J van Veldhuisen; William M Byra; Theodore E Spiro; Hsiaowei Deng; Faiez Zannad; Barry Greenberg
Journal:  Eur Heart J       Date:  2019-11-21       Impact factor: 29.983

9.  Value of the CHA2 DS2 -VASc score for predicting outcome in patients with heart failure.

Authors:  Mony Shuvy; Donna R Zwas; Andre Keren; Israel Gotsman
Journal:  ESC Heart Fail       Date:  2020-07-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.